TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC)

Cervical Cancer Clinical Trial

— ATOMICC  

Official title:

A Randomized, Open Label, Phase II Trial of Anti-PD1, TSR-042, as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03833479
• Other study ID #: GEICO 78-C (ATOMICC)
• Secondary ID: 2018-002155-15
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 28, 2019
• Est. completion date: December 2025

Study information

• Verified date: December 2023
• Source: Grupo Español de Investigación en Cáncer de Ovario
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with locally advanced cervical cancer (LACC) despite definitive chemo-radiotherapy, has a poor progression-free survival (PFS) and overall survival (OS). The hypothesis is that the use of TSR-042, checkpoint inhibitor, as consolidation therapy following concurrent chemo-radiation would increase PFS in these patients. The incorporation of immunotherapy after chemo-radiation is one the best scenarios for this approach, since takes advantages of "the ideal microenvironment" created after radiation. In a similar rationale, the phase 3 study that compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy, showed that progression-free survival was significantly longer with durvalumab than with placebo in all sub-groups regardless of response obtained to chemotherapy, namely patients with stable disease (SD) gained the same benefit that patients with partial response (PR). Due to the aforementioned biology of cervical cancer, the proven activity of anti programmed cell death protein 1 (Anti-PD1) agents in metastatic and/or recurrent cervical cancer and the poor PFS and OS in patients with LACC despite definitive chemo-radiotherapy, we consider to analyze the Anti-PD1 agent, TSR-042 as maintenance therapy after concurrent chemo-radiation (CCRT)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 132
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent before any study-specific procedure

2. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of = 1

3. Participant must be a female = 18 years of age

4. Life expectancy =3 months

5. Participant must have biopsy-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix.

6. Patients must have archival tumor tissue available that is formalin-fixed and paraffin embedded.

7. At diagnosis:

• Federation of Gynecologists and Obstetricians (FIGO) stages IB2, IIA2, IIB with pelvic lymph node involvement: Biopsy-proven pelvic node involvement, 2 or more positive nodes by magnetic resonance imaging (MRI) or computed tomography (CT) (=1.5 cm shortest dimension), 2 or more positive nodes by Positron Emission Tomography (PET) (with standardized uptake values (SUV) =2.5)

• FIGO stages IIIA, IIIB, IVA

• Any FIGO stage with para-aortic lymph node involvement: Biopsy-proven para-aortic node involvement, 1 or more positive nodes by MRI or CT (=1.5 cm shortest dimension), 1 or more positive pelvic nodes by PET (with SUV = 2.5)

8. Subjects must have received combination chemotherapy and radiotherapy (CCRT) with curative intent. Patients must have received at least 4 doses of weekly cisplatin.

9. Patients must have completed definitive treatment, namely chemo-radiation, up to 12 weeks prior to sign the Informed Consent form.

10. Toxicities resulting from chemo-radiation must resolve to = Grade 1 prior to randomization.

11. Participant must have adequate organ function, defined as follows:

• Absolute neutrophil count = 1,500/µL

• Platelets = 100,000/µL

• Hemoglobin = 9 g/dL

• Serum creatinine = 1.5× upper limit of normal (ULN) or calculated creatinine clearance = 50 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN

• Total bilirubin = 1.5× ULN OR direct bilirubin = 1× ULN

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5× ULN unless liver metastases are present, in which case they must be = 5× ULN

• International normalized ratio (INR) or prothrombin time (PT) =1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) =1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

12. Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment.

13. Negative Test Results for Hepatitis

14. Female participant has a negative serum pregnancy test within 72 hours prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 150 days after the last dose of study treatment, or is of nonchildbearing potential.

15. Participant must agree to not breastfeed during the study or for 150 days after the last dose of study treatment.

16. Male partners must agree to use an adequate method of contraception starting with the first dose of study treatment through 150 days after the last dose of study treatment.

17. Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent

Exclusion Criteria:

1. Histological types other than in inclusion criteria, like sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial cancers.

2. FIGO Stage IVB (cancer has spread distantly).

3. Subjects who have undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy.

4. Has not achieved at least a partial response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 after completion of CCRT administered with curative intent.

5. Patients previously treated with chemotherapy except when used concurrently with radiation therapy. Patients who have received either concurrent paclitaxel with radiation therapy or carboplatin/paclitaxel as adjuvant therapy are ineligible for the study.

6. Prior treatment with any anti-vascular endothelial growth factor (anti-VEGF) drug, including bevacizumab, CD137 agonists or immune checkpoint blockade therapies, anti-PD1, or anti-PDL1 therapeutic antibodies or anti-CTLA 4.

7. Patients with a concomitant malignancy other than non-melanoma skin cancer.

8. History of autoimmune disease

9. History of idiopathic pulmonary fibrosis, organizing pneumonia , drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

10. History of interstitial lung disease.

11. Active tuberculosis.

12. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1.

13. Administration of a live, attenuated vaccine within 14 days before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study Influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.

14. Treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1.

15. Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1, Day 1.

16. Women that are breastfeeding or pregnant.

17. Demonstration of any other disease, neurological or metabolic dysfunction, found upon physical examination or laboratory tests involving a reasonable suspicion of the existence of a disease or condition that contraindicates the use of an experimental drug, or that involves an increased risk to the patient of treatment-related complications.

18. No medical or psychiatric illness that may impede the performance of a systemic or surgical treatment

19. Participant must not be simultaneously enrolled in any interventional clinical trial

20. Participant must not have had major surgery = 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects.

21. Participant must not have received investigational therapy = 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.

22. Participant has had radiation therapy encompassing >20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy.

23. Participant must not have a known hypersensitivity to TSR-042 components or excipients.

24. Participant must not have a serious, uncontrolled medical disorder or nonmalignant systemic disease. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent

25. Participant must not have known, symptomatic brain or leptomeningeal metastases

26. Patient experienced = Grade 3 immune-related adverse events (AE) with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.

27. Participant has a known history of human immunodeficiency virus (type 1 or 2 antibodies).

Related Conditions & MeSH terms

• Advanced Cancer
• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Other:
• No Further Treatment
No further treatment

Drug:
• TSR-042
Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months

Locations

Country	Name	City	State
Spain	H Vall d'Hebron	Barcelona
Spain	Hospital Clínic	Barcelona
Spain	H Reina Sofía Cordoba	Cordoba
Spain	Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea	Donostia	Gipuzkoa
Spain	Hospital General Universitario de Elche	Elche	Alicante
Spain	ICO Girona	Girona
Spain	ICO Hospitalet	Hospitalet del Llobregat
Spain	Clinica Universitaria de Navarra	Madrid
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Ramon y Cajal	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Virgen de la Victoria	Málaga
Spain	Hospital Clinico Universitario Virgen Arrixaca	Murcia
Spain	Hospital Universitario Morales Meseguer	Murcia
Spain	Hospital Son Espases	Palma De Mallorca
Spain	Hospital Son Llatzer	Palma De Mallorca
Spain	H. Parc Taulí	Sabadell
Spain	Hospital Marqués de Valdecilla	Santander
Spain	Hospital Universitario Virgen del Rocío	Sevilla
Spain	Hospital de Terrassa	Terrassa
Spain	Hospital Clínico Universitario de Valencia	Valencia
Spain	Hospital La Fe	Valencia	Comunidad Valenciana
Spain	Instituto Valenciano de Oncología	Valencia
Spain	Hospital Álvaro Cunqueiro	Vigo	Pontevedra
Turkey	Ankara City Hospital	Ankara	Anadolu Bölgesi
Turkey	Ankara Oncology Training and Research Hospital	Ankara	Anadolu Bölgesi
Turkey	Hacettepe University	Ankara	Anadolu Bölgesi
Turkey	Acibadem Maslak Hospital	Istanbul	Sariyer

Sponsors (3)

Lead Sponsor	Collaborator
Grupo Español de Investigación en Cáncer de Ovario	Apices Soluciones S.L., TESARO/GSK

Countries where clinical trial is conducted

Spain,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival	Time from the date of randomization to the date of first documentation of disease progression or death due to any cause, whichever occurs first based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)	30 months
Secondary	Frequency and severity of adverse events (AEs)	Incidence, nature and severity of adverse events (AEs) assessed by CTCAE version 4.03	30 months
Secondary	Overall survival (OS)	Time from the date of randomization to the date of death due to any cause	30 months
Secondary	Patient reported outcomes (PROs) of health-related quality of life (HRQOL)	Mean changes from baseline score assessed by the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx)	30 months
Secondary	Patient reported outcomes (PROs) of health-related quality of life (HRQOL)	Mean changes from baseline score assessed by EQ -5D-5L.	30 months
Secondary	Patient reported outcomes (PROs) of fatigue	Mean changes from baseline score assessed by the PROMIS-Cancer-Fatigue Short Form 4a.	30 months
Secondary	Patient reported outcomes (PROs) of pain	Mean changes from baseline score assessed by a single item of the Brief Pain Inventory (BPI).	30 months